Pierre Fabre Pharmaceuticals, Inc.

Pierre Fabre Pharmaceuticals, Inc. is a subsidiary of Pierre Fabre Laboratories, the second largest independent pharmaceutical group in France. Pierre Fabre is present in 42 countries and has distribution in over 130 countries worldwide. Pierre Fabre Pharmaceuticals is committed to the absolute requirement of quality, efficacy and safety of its drugs, research and development of dermatological products, and partnering with dermatologists and pediatricians.

In 2014, Pierre Fabre Pharmaceuticals received FDA approval for HEMANGEOL ™ (propranolol hydrochloride), an oral solution indicated for the treatment of proliferating Infantile Hemangioma requiring systemic therapy.

To find out more about HEMANGEOL ™ and Pierre Fabre Pharmaceuticals, please stop by our booth in the exhibit hall or visit www.hemangeol.com.

Brands: HEMANGEOL™ (propranolol hydrochloride) oral solution is a FDA approved drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

Learn More at Pierre Fabre Pharmaceuticals, Inc.

Contact Information

Joseph Lanza
(857) 309-8139
joseph.lanza@pierre-fabre.com